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A B S T R A C T
Background: Recent evidence has suggested that chemsex (the use of mephedrone, crystal methamphetamine
and -hydroxybutyrate/ -butryolactone (GHB/GBL) to enable, enhance and prolong sexual interactions) has
increased among men having sex with men (MSM) attending sexual health clinics in large UK cities. To date
there has been no data from the UK or Europe that describes changes in chemsex over time within a cohort of
MSM.
Methods: The prospective cohort study, Attitudes to and Understanding Risk of Acquisition of HIV over Time
(AURAH2), collected online questionnaire data from HIV negative or undiagnosed MSM (at enrolment) from
2015 to 2018, recruited from sexual health clinics. We aim to investigate changes in chemsex, three individual
drugs associated with chemsex, frequency of chemsex sessions and measures of sexual behaviour, among the
cohort of MSM over the study’s 3 year follow-up period.
Results: In total 622 MSM completed at least one online questionnaire for the AURAH2 study, of which 400
(64.3%) were still engaged with the study within the last six months of follow-up. Prevalence of chemsex sig-
nificantly declined during the follow-up from 31.8% (198/622) at the first online questionnaire, to 11.1% (8/72;
p< 0.001) at the 9th. This decline was reflected in the proportion of MSM reporting use of two of the three
individual chemsex drugs: mephedrone use had significantly declined from 25.2% at the first online ques-
tionnaire to 9.7% (p< 0.001) at the 9th, GHB/GBL use had also declined from 19.9% to 8.3% (p=0.001).
While crystal methamphetamine use declined, but not significantly (11.1%–6.9% [p= 0.289]). Most measures
of sexual behaviour (any anal sex, group sex, recent HIV test and bacterial STI) also tended to decline over the
follow-up period, with the exception of CLAI with more than one and more than two partners.
Conclusions: Chemsex and use of two individual chemsex drugs (mephedrone and GHB/GBL) significantly de-
clined over time among individuals in the study, alongside most measures of sexual behaviour with the exception
of those related to CLAI. Focusing health promotion and HIV prevention, such as awareness of post-exposure
prophylaxis (PEP) and access to pre-exposure prophylaxis (PrEP), on MSM that report chemsex, and in particular
problematic chemsex, would be highly beneficial, potentially only necessary for a relatively short period of time
for individuals, and could have long term benefits for HIV and STI prevention.
Introduction
Chemsex, defined in the UK as the use of mephedrone, crystal me-
thamphetamine and -hydroxybutyrate/ -butryolactone (GHB/GBL)
to enable, enhance and prolong sexual interactions (Bourne, Reid,
Hickson, Torres Rueda, & Weatherburn, 2014), has been described
predominantly among men who have sex with men (MSM) and has
potential implications for public health due to its associations with high
risk sexual behaviour (Hegazi et al., 2017; McCarty-Caplan, Jantz, &
Swartz, 2014; Sewell et al., 2017), sexually transmitted infections (STI)
and HIV transmission (Hirshfield, Remien, Walavalkar, & Chiasson,
2004; Macdonald et al., 2008; Ostrow et al., 2009; Pufall et al., 2018;
Sewell et al., 2017). Qualitative data have described motivations and
values associated with chemsex among MSM which include, enhancing
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the quality of sex and increasing the ability to engage in type of sex that
is desired (Weatherburn, Hickson, Reid, Torres-Rueda, & Bourne,
2017). However, research has also highlighted issues around sexual
consent in the context of drugs, as well as difficulties in negotiating sex,
particularly in group sex environments (Bourne et al., 2015). Whilst not
all chemsex is problematic in nature, recent evidence has demonstrated
that MSM attending sexual health clinics who disclosed chemsex par-
ticipation had a five-fold increase in the odds of being newly diagnosed
with HIV-infection (Pakianathan et al., 2018). For this reason, chemsex
is currently a key area of focus for Public Health England (PHE) with
the aim of improving the health and wellbeing of MSM (PHE action
plan, 2015-16 Promoting the health and wellbeing of gay, bisexual and
other men who have sex with men, 2015), as well as to develop best
practice in terms of specialist support services.
Although, there is some evidence that drug use and chemsex is more
common among HIV positive MSM (Pakianathan et al., 2018; Stuart,
2013), cross-sectional data from 2013/14 and 2015/16 indicated an
increase in the proportion of HIV negative or undiagnosed MSM at-
tending large, urban, sexual health services reporting use of drugs ty-
pically associated with chemsex (Sewell et al., 2018), and recent re-
search has shown that chemsex is widespread across the UK (Wiggins
et al., 2018), and not confined to urban areas, where the majority of
data have been collected (Edmundson et al., 2018). Most previous
cross-sectional studies from the UK have collected information on use of
chemsex drugs among MSM, but not the context of use (whether these
drugs were used just prior to or during sexual activity) (Edmundson
et al., 2018), despite evidence that drugs associated with chemsex, in
particular mephedrone and GHB/GBL, are used in a range of other
settings outside of a sexual context (Frankis, Flowers, McDaid, &
Bourne, 2018; Melendez-Torres et al., 2018). Furthermore, as yet, there
have been no longitudinal studies from the UK or Europe, able to detect
changes in frequency of chemsex at an individual level over time, which
would help contextualise cross-sectional prevalence data. Although
strong associations between chemsex and measures of sexual risk be-
haviour have been reported (Sewell et al., 2017), there is a lack of data
that places chemsex patterns in the context of other sexual behaviour
patterns within the same period of time. In this paper we present data
from the prospective cohort study, Attitudes to and Understanding Risk
of Acquisition of HIV over time (AURAH2), which recruited HIV ne-
gative or undiagnosed MSM from sexual health clinics in London and
Brighton (Sewell et al., 2016). We report changes in chemsex, and use
of individual chemsex drugs, in the cohort over the time of the study,
and describe changes in sexual behaviour over the same time period.
We further investigate factors associated with chemsex and the in-
dividual chemsex drugs, among AURAH2 participants.
Methods
The AURAH2 study was a prospective cohort study that recruited
HIV negative or undiagnosed MSM from sexual health clinics in London
and Brighton (56 Dean Street clinic, London, Mortimer Market centre,
London and Claude Nicol clinic, Brighton) from November 2014 to
April 2016. Participants completed a baseline paper questionnaire in
clinic, and subsequent four monthly (from online registration) online
questionnaires, available from March 2015, for up to three years until
March 2018. The four monthly questionnaires captured information on
HIV status, HIV testing history, recent sexual behaviour (number of
condomless sex partners, group sex, status of partners and whether on
anti-retroviral therapy (ART) (if partner(s) were HIV+), health and
lifestyle factors including recreational drug use and chemsex, and STI
diagnoses (all with a 3 month recall period). Participants were also
invited to complete a longer, online, annual questionnaire that col-
lected the same information as the four monthly questionnaire plus
additional information on post exposure prophylaxis (PEP) and pre-
exposure prophylaxis (PrEP) use (in the past year), relationship status,
mental health (using the Patient Health Questionnaire-9 (PHQ-9)
(Kroenke, Spitzer, & Williams, 2001) and Generalised Anxiety Disorder-
7 (GAD-7)(Spitzer, Kroenke, Williams, & Lowe, 2006)) and alcohol
consumption (World Health Organisation alcohol screening tool audit
(AUDIT-C score) (Babor, Higgins-Biddle, Saunders, & Monteiro, 2001)).
Methodological details for the AURAH2 study have been published
elsewhere (Sewell et al., 2016).
Ascertainment of chemsex drug use
At each four monthly online questionnaire, participants were asked
to self-report whether they had ‘used drugs before or during sex
(chemsex)’ with a recall period of ‘last three months’, and if so, to select
which chemsex drugs from the following list: mephedrone, GHB/GBL,
crystal methamphetamine, other (with space for free text). Participants
were then asked ‘Approximately how often did you have chemsex in the
last 3 months?’ with the answer options of, ‘Once’, ‘Monthly’ or
‘Weekly’.
Sexual risk behaviours, STI diagnoses and HIV testing
Seven measures of sexual risk behaviour and related activities were
derived from the four monthly online questionnaires. Anal sex referred
to anal sex with men throughout the questionnaires. The first measure
was (i) any anal sex within the past three months, subsequent measures
of condomless anal intercourse (CLAI) in the past three months were
defined as: (ii) CLAI with one or more partners, (iii) CLAI with two or
more partners, (iv) CLAI with partners of unknown HIV status. Three
additional measures related to sexual behaviour (in the past three
months) were defined as: (v) diagnosis with a bacterial STI
(Gonorrhoea, Chlamydia, Syphilis, and/or Lymphogranuloma
Venereum (LGV)), (vi) group sex, and (vii) recent HIV test.
Online questionnaire completion
Two reminder emails spaced over a two week period were sent to
participants when they were due to complete a questionnaire, followed
by a text message a week after the second email (if the participant had
provided a phone number at enrolment). If a participant missed a
questionnaire at any time during follow-up they were still invited to
complete subsequent questionnaires and were only withdrawn from the
study if they specifically emailed the study manager stating their de-
cision to withdraw. Participants who completed a first online follow-up
questionnaire in March 2015 had the option of completing up to 9
online questionnaires, whereas participants who joined the study
afterwards only had the option of completing fewer, as the online
follow-up finished in March 2018.
Statistical analysis plan
Analyses were based on all MSM that completed an online ques-
tionnaire (n=622), using pooled data from all the online follow-up
questionnaires; therefore, multiple responses from individuals were
included. Firstly, we examined the associations of sociodemographic,
health, lifestyle characteristics and PEP, PrEP, HIV status and calendar
year and time in the study with chemsex (binary dependent variable)
using univariate generalized estimating equations (GEE) Poisson model
with robust variance estimation, with an exchangeable covariance
matrix to produce prevalence ratios (PR). In these and subsequent
analyses, baseline values of sociodemographic variables were used
throughout follow-up, as these were not collected subsequently. For all
other variables, information from the relevant follow-up questionnaire
was used. Then, in multivariable analysis, using pooled data from the
online follow-up questionnaires, we assessed the association between
chemsex (binary, dependent variable) and time in the study, adjusting
for socio-demographic factors, that could not be influenced by chemsex:
age group (<25, 25–29, 30–34, 35–39, 40–44, ≥45 years), country of
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birth and ethnicity (white UK born, non-white UK born, white non-UK
born, non-white non-UK born), self-reported sexual identity (gay or
bisexual/other), university education (yes or no/missing) and study site
(The Mortimer Market Centre, London; 56 Dean Street Clinic, London;
The Claude Nicol Centre, Brighton).
To examine changes over time in the study in chemsex and in-
dividual chemsex drugs, we considered the proportion of those who
reported chemsex at each 4 monthly online questionnaire, using the
total number who responded to that questionnaire as the denominator.
Univariate generalized estimating equations (GEE) Poisson model with
robust variance estimation was used to see if the changes in chemsex
and individual chemsex drugs over the follow-up period were sig-
nificant. This method was also used to investigate changes in the seven
measures of sexual behaviour over time.
Three sensitivity analyses were conducted to better understand
whether results were affected by lost to follow-up over time. The first
analysis included only MSM who completed a questionnaire within the
final six months of the study follow-up period compared to the main
results. The second sensitivity analysis investigated whether chemsex
predicted being lost to follow-up. Two variables were created, ‘lost to
follow-up’ (stopped completing online questionnaires and did not re-
sume) and ‘missed the next questionnaire’ (missed the next ques-
tionnaire). The GEE Poisson model used in the main analysis was uti-
lised to explore whether chemsex predicted being ‘lost to follow-up’ or
‘missed the next questionnaire’. For the third sensitivity analysis, the
last observation for the chemsex variable was carried forward where
online questionnaires were missing and the same adjustment and
Poisson model was used as in the main analysis. All analysis was con-
ducted in Stata statistical software V.13.
Results
Characteristics of online participants
Of the 1167 MSM who consented to and completed the AURAH2
study baseline questionnaire in clinic, 622 (53.2%) went on to complete
at least one online follow up questionnaire. Of these, 64.3% (400/622)
remained engaged with the study throughout (completed a ques-
tionnaire within the last 6 months of the study follow-up period). In
total, all participants that completed at least one online questionnaire
contributed a total of 1423 person-years of follow-up. Table 1 shows
sociodemographic, health and lifestyle characteristics, sexual beha-
viour, PEP, PrEP and HIV testing in the AURAH2 cohort.
Socio-demographic, health and lifestyle characteristics, sexual behaviour,
PEP, PrEP and HIV testing, among participants in the AURAH2 study, and
those that reported chemsex use at first online questionnaire of online
(n= 622)
The median age among participants who completed at least one
online questionnaire (n=622) was 34 (standard deviation [SD]: 11.3)
years, 579 (94.5%) identified as gay and 34 (5.5%) identified as bi-
sexual or other, most (511, 83.8%) were of white ethnicity and over
three quarters (472 (76.7%)) were educated to university level (see
Table 1). The prevalence of chemsex associated drug use at baseline
among MSM who did not complete any online questionnaires (n=545)
was comparable (29.4%) to that among MSM that completed at least
one online questionnaire (32.3%); as was the prevalence of individual
chemsex drugs that were reported among MSM who did not complete
an online questionnaire compared to those that did, mephedrone
(26.8% vs 28.5%), GHB/GBL (17.4% vs 20.3%) and crystal metham-
phetamine (9.4% vs 10.0%) (see supplementary material 1, Table 3).
Fifteen men self-reported a new HIV diagnosis during the 3-year online
follow-up period.
When examining associations with chemsex using pooled data from
all the follow-up questionnaires, a number of factors were found to be
associated with chemsex. In unadjusted analysis (Table 2). There was a
tendency for prevalence of chemsex to be higher among participants
not born in the UK and among those not in an ongoing relationship.
Clinically significant symptoms of depression (PR 1.47 95%CI: 1.08,
2.00) or anxiety (PR 1.49 95%CI: 1.10, 2.01) (at annual questionnaires)
were both associated with chemsex, as was the use of PEP (PR 1.43
95%CI: 1.09, 1.87) or PrEP (PR 1.63 95%CI: 1.28, 2.09). Age and
markers of socioeconomic status were not associated with chemsex.
Chemsex prevalence significantly decreased as time in the study in-
creased and as calendar year increased (see Table 2.)
Associations of chemsex and individual chemsex drugs with time (calendar
year) over the AURAH2 follow-up period
In unadjusted analysis we found a strong negative association
Table 1
Socio-demographic, health and lifestyle characteristics, sexual behaviour, PEP,
PrEP and HIV testing, among MSM in the AURAH2 study that completed at least
one follow-up questionnaire, (n=622 unless indicated).
Characteristic Category n(%)
Age1 (years) [n=610] <25 132 (21.6%)
25-29 86 (14.1%)
30-34 121 (19.8%)
35-39 89 (14.6%)
40-44 69 (11.3%)
45+ 113 (18.5%)
Born in the UK and white ethnicity1
[n=610]
Yes, white 317 (52.0%)
Yes, non-white 29 (4.7%)
No, white 194 (31.8%)
No, non-white 70 (11.5%)
Money to cover basic needs1 [n=615] All of the time 509 (82.8%)
Most of the time 81 (13.2%)
Sometimes/no 25 (4.1%)
University education1 [n=615] Yes 472 (76.7%)
No 143 (23.2%)
Employed1 [n=615] Yes 547 (88.9%)
No 68 (11.1%)
Housing status1 [n=606] Home owner 200 (33.0%)
Renting 328 (54.1%)
Unstable/other 78 (12.9%)
Sexual identity1 [n=610] Gay 579 (94.5%)
Bisexual/other 34 (5.5%)
Ongoing relationship1 [n=615] Yes 257 (41.8%)
No 358 (58.2%)
Higher risk alcohol consumption (WHO
AUDIT-C >=6) 1 [Missing n=7]
Yes 80 (12.9%)
No/missing 542 (87.1%)
Clinically significant depressive symptoms
(PHQ-9 score >=10) 1 [Missing
n=7]
Yes 75 (12.1%)
No/missing 547 (87.9%)
Clinically significant anxiety symptoms
(GAD& score>=10)1 [Missing n=7]
Yes 57 (9.2%)
No/missing 565 (90.8%)
Any anal sex2 [missing n=4] Yes 562 (90.3%)
No/missing 60 (9.1%)
CLAI with 1 or more partner(s) 2 [missing
n=4]
Yes 413 (66.4%)
no/missing 209 (33.6%
CLAI with 2 or more partner(s) 2 [missing
n=4]
Yes 243 (39.1%)
No/missing 379 (60.9%)
CLAI with partner(s) of unknown status2
[missing n=10]
Yes^ 210 (33.8%)
no/missing 412 (66.2%)
Chemsex2 [missing n=4] Yes 198 (32.0%)
No/missing 424 (68.2%)
Diagnosed with bacterial* STI2 [missing
n=4]
Yes 164 (26.4%)
no/missing 458 (73.6%)
Group sex2 [missing n=4] Yes 203 (32.6%)
no/missing 419 (67.4%)
Recent HIV test2 [missing n=10] Yes 476 (76.5%)
no/missing 146 (23.5%)
1from baseline questionnaire data;2from first 4 monthly questionnaire data.
CLAI: Condomless anal intercourse.
^It means they report not knowing the status of some or none of their partners;
*bacterial STI (Gonorrhoea, Chlamydia, Syphilis, and/or Lymphogranuloma
Venereum (LGV).
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between time spent in the study and chemsex, and use of mephedrone
and GHB/GBL, but not crystal methamphetamine (see Table 3). After
adjusting for age, country of birth and ethnicity, sexual identity, uni-
versity education and study site, we found the strength of this asso-
ciation remained for chemsex, and the individual drugs mephedrone
and GHB/GBL, with crystal methamphetamine use remaining not sig-
nificantly associated.
Changes in prevalence of chemsex over time in the study
Overall, chemsex and the use of two (mephedrone and GHB/GBL) of
the three individual chemsex drugs significantly declined over the
follow up period of the study (see Fig. 1). The prevalence of chemsex at
the first online questionnaire was 31.8% (198/622), which steadily and
significantly declined over time to 11.1% (8/72; p< 0.001) among
MSM who completed the 9th questionnaire of follow-up. This decline
was reflected in the proportion of MSM reporting use of two individual
chemsex drugs: mephedrone use significantly declined from
25.2%–9.7% (p<0.001), GHB/GBL also significantly declined from
19.9% to 8.3% (p=0.001). However, crystal methamphetamine use
marginally decreased, but not significantly, 11.1% at the first online
questionnaire and 6.9% at the 9th online questionnaire (p= 0.2893).
These results remained similar in the first sensitivity analysis that
only included MSM who had completed a questionnaire within the final
six months of the study follow-up period (supplementary material 2,
Figure 4).
In the second sensitivity analysis, we explored whether there was a
selective loss over time of MSM engaging in chemsex. There was no
association of chemsex with loss to follow-up (stopped and did not
resume online questionnaires) (PR 1.04 (95%CI: 0.89, 1.24) or with
missing the next online questionnaire (PR 1.02 (95%CI: 0.90, 1.16)
(supplementary material 3, Table 4). In the third sensitivity analysis, in
which the last observation for the chemsex variable was carried forward
Table 2
Unadjusted associations of sociodemographic and lifestyle characteristics, PEP,
PrEP, HIV status, calendar year and time in the study, with chemsex during
follow-up in the AURAH2 study. Analysis using pooled data from all available
follow-up questionnaires.
Factor (number of observations) Prevalence Ratio
(95%CI)
Age* (years) (observations 3239) <25 1
25-29 0.83 (0.66, 1.05)
30-34 0.95 (0.73, 1.26)
35-39 1.03 (0.76, 1.40)
40-44 1.00 (0.70, 1.44)
45+ 0.76 (0.54, 1.08)
p=0.298*
p=0.278**
Born in the UK and white ethnicity1
(observations 3239)
Yes, white 1
Yes, non-white 0.90 (0.50, 1.64)
No, white 1.25 (0.97, 1.61)
No, non-white 1.46 (1.06, 2.00)
p=0.066*
Money to cover basic needs1
(observations 3257)
All of the time 1
Most of the time 1.05 (0.77, 1.45)
Sometimes/no 1.06 (0.63, 1.77)
p=0.931*
p=0.716**
University education 1 (observations
3257)
No 1
Yes 0.96 (0.74, 1.23)
p=0.546*
Employed 1 (observations 3257) No 1
Yes 1.12 (0.77, 1.63)
p=0.510*
Housing status1 (observations 3211) Home owner 1
Renting 0.96 (0.74, 1.23)
Unstable/other 1.02 (0.73, 1.44)
p=0.902*
p=0.828**
Sexual identity1 (observations 3247) Bisexual/other 1
Gay 1.13 (0.69, 1.84)
p=0.628*
Ongoing relationship2 (observations
937)
No 1
Yes 0.79 (0.62, 1.02)
p=0.068*
Higher risk alcohol consumption2
(modified WHO AUDIT-C >=6)
(observations 942)
No/missing 1
Yes 0.94 (0.65, 1.38)
p=0.768*
Clinically significant depressive
symptoms2 (PHQ-9 score >=10)
(observations 942)
No/missing 1
Yes 1.47 (1.08, 2.00)
p=0.014*
Clinically significant anxiety
symptoms2 (GAD& score>=10)
(observations 942)
No/missing 1
Yes 1.49 (1.10, 2.01)
p=0.008*
PEP use2 (observations 942) No/missing 1
Yes 1.43 (1.09, 1.86)
p=0.009*
PrEP use2 (observations 942) No/missing 1
Yes 1.63 (1.28, 2.09)
p<0.001*
HIV status (observations 3277) Negative 1
Positive 0.87 (0.55, 1.38)
Don’t know/
missing
1.01(0.83, 1.23)
P= 0.8383*
Year (observations 3262) 2015 1
2016 0.82 (0.74, 0.90)
2017 0.77 (0.69, 0.86)
2018 0.73 (0.62, 0.87)
p<0.001*
p<0.001**
Time in the study (since 1st online
questionnaire) (observations 3277)
0 months 1
4 months 0.90 (0.81, 1.00)
8 months 0.79 (0.69, 0.89)
12 months 0.83 (0.73, 0.95)
16 months 0.71 (0.61, 0.83)
20 months 0.78 (0.68, 0.89)
24 months 0.77 (0.67, 0.89)
28 months 0.68 (0.56, 0.81)
32 months 0.54 (0.41, 0.70)
Table 2 (continued)
Factor (number of observations) Prevalence Ratio
(95%CI)
p< 0.001*
p< 0.001*
1from baseline questionnaire data; 2from annual questionnaire data; *p value
from Poisson GEE model;**p value from Poisson GEE model including the
predictors as continuous variable.
Table 3
Associations of time since first online questionnaire with chemsex, and in-
dividual chemsex drugs, during follow-up in the AURAH2 study. Analysis using
pooled data from all available follow-up questionnaires.
Dependent
variable
Unadjusted* PR for
visit (95%CI)
p value Adjusted* PR for
visit (95%CI)
p value
Chemsex 0.95 (0.93, 0.97) <0.001 0.95 (0.93, 0.97) <0.001
Mephedrone 0.89 (0.86, 0.92) <0.001 0.89 (0.86, 0.92) <0.001
GHB/GBL 0.96 (0.93, 0.98) 0.001 0.96 (0.93, 0.99) 0.003
Crystal Meth** 1.02 (0.98, 1.06) 0.289 1.01 (0.97, 1.05) 0.564
CI: confidence interval; PR: prevalence ratio.
*observations in each model: Unadjusted=3277, Adjusted= 3229.
**Methamphetamine No missing data for question on chemsex at any online
questionnaire among respondents.
Adjusted: sociodemographic characteristics that could not be influenced by
chemsex :time-updated age (<25, 25–29, 30–34, 35–39, 40–44, ≥45 years),
country of birth and ethnicity (white UK born, non-white UK born, white non-
UK born, non-white non-UK born), self-reported sexual identity (gay or bi-
sexual/other), university education (yes or no/missing) and study site (The
Mortimer Market Centre, London; 56 Dean Street Clinic, London; The Claude
Nicol Centre, Brighton).
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to fill in missing data, in adjusted analyses the decline over calendar
year in chemsex remained (data not shown).
Within-person changes in frequency of chemsex over time in the study
Fig. 2 shows the frequency of chemsex reported over the follow-up
period according to frequency of chemsex reported at the first online
questionnaire. There was some variation in levels of chemsex use within
individuals over time in the study, and a general tendency for use to
decline over time. At the first online questionnaire, around two thirds of
MSM (68.3%; 425/622) reported no chemsex (in the past 3 months), 70
out of 622 11.3%) reported chemsex ‘Once’, 95 MSM (15.3%) reported
chemsex ‘Monthly’ and 32 (5.1%) reported chemsex ‘Weekly’. At each
questionnaire(time-point) over 65% had reported no chemsex at first
online questionnaire and continued to report no chemsex. In total, of
the 72 MSM who replied to the 9th questionnaire 90.3% (65/72) re-
ported ‘No chemsex’ at the 9th questionnaire, 1 (1.4%) reported it
‘Once’ and 6 (8.3%) reported it ‘Monthly’, none reported it ‘Weekly’ at
the 9th questionnaire covering the most recent 3 month period(Fig. 2).
Changes in sexual risk behaviours, STI diagnoses and HIV testing, over time
Overall the measures of sexual behaviour and associated beha-
viours, tended to decline over time among the cohort (see Fig. 3), with
only those related to CLAI slightly increasing (CLAI with 1 or more
partner and CLAI with 2 or more partners). Any anal sex declined from
90.9% at the 1 st questionnaire to 86.5% at the 9th questionnaire, while
CLAI with one or more partners increased from 66.4%–70.8% at the 9th
Fig. 1. Prevalence of chemsex, and individual chemsex drugs over time in the study, among MSM in the AURAH2 study (n= 3277 questionnaires)*.
*No missing data for question on chemsex at any online questionnaire among respondents
Decr: decreasing;
Fig. 2. Within-person changes in frequency of chemsex over time in the study among MSM in the AURAH2 study (n=3277 questionnaires).
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questionnaire and group sex decreased from 32.6%–25.5%. Reporting a
bacterial STI had significantly decreased from 26.4%–9.7% over the
follow up period (p<0.001). Reporting a recent HIV test (within the
past 3 months) had also significantly declined, although the high pre-
valence of HIV testing at the first online questionnaire (76.5%) could be
a reflection of the study process whereby participants were invited (via
email) to complete their first online questionnaire within 3 months of
recruitment to the study in-clinic, where it is likely they were offered an
HIV test.
Discussion
This paper provides the first longitudinal analysis of chemsex
among a cohort of MSM in Europe and is provided in the context of
changes in sexual behaviour over the same time period. Our results
suggest a decline in prevalence of chemsex, and chemsex specific drugs
such as mephedrone and GHB/GBL, over time among MSM in the study;
even when we restrict to those who remained engaged with the study
over the 3-year follow-up period. Despite some selective drop-out of
MSM who reported chemsex in the study, we found no association
between chemsex and being lost to follow-up or missing the next study
questionnaire. This decline is reflected in the patterns of reported fre-
quency of chemsex at each online follow-up (‘No chemsex, ‘Once’,
‘Monthly’, ‘Weekly’ [past 3 months]) over the same period which
showed an increase in MSM reporting ‘No chemsex’ from the first online
questionnaire to the last. Although it is difficult to attribute a direct
cause for this decline, one explanation could be found in the clinics that
AURAH2 recruited from, which are specialist centres for chemsex
support where interventions are specifically tailored to MSM reporting
chemsex (Sewell et al., 2018). As such our results may be a reflection on
the effectiveness of these services at providing valuable support and
interventions to reduce chemsex among a specific group of MSM. Fur-
thermore, engagement with questionnaires that encourage reflection on
behaviour may play a factor in study participants becoming more
conscious of the consequences of their choices, which could have led to
behaviour change (McCambridge & Kypri, 2011); and may partly ex-
plain the decline in chemsex and individual chemsex drug use wit-
nessed in this cohort. Another potential explanation for the decline in
chemsex in the cohort over time in the study is regression to the mean.
In other words, men may have been recruited to the study at a time of
particularly high risk behaviour, risk which would then tend to decline
with time. It appears that men were more likely to have condomless sex
with more than one and more than two partners as the study pro-
gressed, but it became less likely that this sex involved a partner of
unknown HIV status, group sex and chemsex drugs.
The number of self-reported new HIV diagnoses (15 sero-conver-
sions) among our cohort over the three-year follow-up period is low,
even when considered in the context of the steep fall in HIV diagnoses
reported by both 56 Dean Street and Mortimer Market clinic (Brown
et al., 2017) during the same time period as the study follow-up. Dif-
ferently from (Pakianathan et al., 2018), we did not find an association
between reporting chemsex and becoming newly diagnosed with HIV in
unadjusted analysis, despite a strong association with PEP and PrEP
use. Similarly to what we reported for the AURAH study (cross-sec-
tional) on use of chemsex drugs (Sewell et al., 2017), we found here a
significant association between depression and anxiety and chemsex. It
has been suggested that use of recreational drugs among MSM could be
part of a behaviour to cope with a feeling of being part of a minority
and other stressors (Meyer, 1995; Wolitski, Stall, & Valdiserri, 2008).
The estimated prevalence of chemsex at the start of online follow up
in the AURAH2 study (32.0%) is similar to that estimated in the cross-
sectional analysis of the larger sample (n= 1031) of MSM who com-
pleted a baseline paper questionnaire in-clinic in 2015/2016 during
recruitment to the study (32.3%) (Sewell et al., 2018), and is sub-
stantially higher than the prevalence of chemsex drug use observed in
the cross-sectional AURAH study conducted in 2013/2014 (prevalence
among MSM attending 20 sexual health clinics across England: 21.8%,
prevalence among MSM attending the same three sexual health clinics
included in the AURAH2 study: 24.2%) (Sewell et al., 2017, 2018).
Compared to other clinic based studies, the prevalence of chemsex at
the start of online follow-up in the AURAH2 study is higher than that
reported by a recent retrospective case note review from 2014/2015
among MSM (n= 1734) attending sexual health services in a different
area of London (16.5%) (Pakianathan et al., 2018), and similar to that
reported among HIV positive MSM in-patients admitted to an HIV unit
in 2014/2015 (31%, n=42) also in London (Elliot, Singh, Tyebally,
Gedela, & Nelson, 2017). This high prevalence of chemsex at the start of
online follow-up in the AURAH2 study could also be related to the lo-
cation of the clinics (London and Brighton), that the study population
were recruited from. Both cities were in the top three among 44 cities in
Europe where use of 4-chems was reported highest among MSM in the
2010 European MSM Internet Survey, 2010 (Schmidt et al., 2016).
Furthermore, two of the clinics from which participants were recruited
from (56 Dean Street and Mortimer Market) are renowned for their
chemsex support services in London, which may have resulted in a
larger number of MSM who engage in chemsex, opting to attend them.
However, the declining trend in chemsex in this longitudinal analysis,
from 31.8%–11.1%, over the 3 year follow-up period of the AURAH2
Fig. 3. Prevalence of measures of sexual behaviour1 over time in the study among MSM in the AURAH2 study (n= 3277 questionnaires).
*CLAI= condomless anal intercourse and Missing data were treated as no, the number of missing data was limited (see missing data for visit 1 in Table 1)
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study, indicates that MSM attending sexual health clinics who report
chemsex, would appear to do so for specific, relatively short periods of
time, during which regular attendance at sexual health clinics for STI
monitoring, HIV testing and access to PEP and PrEP would be highly
beneficial due to the high risk sexual behaviours (Hegazi et al., 2017;
Sewell et al., 2017). Due to the relatively short follow-up period of the
online study (3 years) and the loss to follow-up, it is not known whether
MSM who stopped reporting chemsex during the course of the AURAH2
online follow-up period have remained abstinent from chemsex or have
since reinitiated. Further longitudinal studies with extended follow-up
periods would help elucidate this information and qualitative data on
stopping and re-initiating chemsex would be beneficial to contextualise
our results.
There is limited longitudinal data on chemsex patterns and trajec-
tories among MSM at national or international level with which to
compare our results to. The Australian, Following Lives Undergoing
Change (Flux) Study, is an online prospective cohort study (n=1710)
that commenced in 2014/2015 and collects biannual data on licit and
illicit drug use among Australian MSM recruited online through social
media, gay community websites and gay sexual networking websites
(Hammoud et al., 2017). Recent results from the Flux study described
an increase over calendar time in concurrent use of methamphetamines,
Viagra™ and other erectile dysfunction medications, and Truvada™ as
PrEP (Hammoud et al., 2018), however no results on chemsex have yet
been published. Furthermore, the major difference in study samples
(Flux used an online convenience sample whilst AURAH2 recruited
from clinics) and the drugs included in each analysis (Flux: metham-
phetamine, Viagra™ and Truvada™, AURAH2: mephedrone, crystal me-
thamphetamine and GHB/GBL) make it difficult to draw comparisons.
A major strength of this study is the large sample size and regular
recall period that was used to capture event-level data on chemsex. This
allowed us to investigate trends in patterns and frequency of chemsex
and individual chemsex drugs. The online retention of participants that
registered and completed an online questionnaire, was not optimal,
however 64.3% of participants completed an online questionnaire
within the last six months of the study follow-up period, and there were
no significant differences in the main analyses when restricting to
people who had completed a questionnaire in the last 6 months of
follow-up. Additionally, collecting sensitive and personal information
on drug use and sexual behaviour online may have reduced potential
social desirability bias (DiClemente, Swartzendruber, & Brown, 2013).
As with any study collecting self-reported data, results may be influ-
enced by recall bias, despite the time frame for chemsex and the sexual
behaviour measures being within the past 3 months, the maximum
period of recall recommended to obtain accurate self-reports (Napper,
Fisher, Reynolds, & Johnson, 2010). Potentially both a strength and
limitation of the study was the recruitment of participants attending
sexual health clinics renowned for their focus on integrating substance
use services with sexual health services, and the location of these clinics
being in large, urban centres, noted for their gay communities, London
and Brighton. Whilst understanding trends in chemsex and sexual be-
haviour among clinic attendees in these clinics may elucidate patterns
in similar high-density areas populated by MSM, it limits the gen-
eralisability of our results to include smaller towns and cities and rural
areas where service provision is required but often not supplied in the
same capacity (Wiggins et al., 2018). Additionally, our highly educated,
economically stable cohort may not be representative of the wider MSM
community, thus limiting the generalisability of our results further.
Furthermore, we recognise that our results may not reflect trends in
chemsex trajectories and patterns among MSM who are not engaged
with sexual health services, where potential for problematic harms as-
sociated with chemsex may be greater, despite the risk group being the
potential smaller (Melendez-Torres et al., 2018).
Conclusions and implications
This is the first study from the UK and Europe to describe changes in
patterns of chemsex, frequency of chemsex and sexual behaviour over
time among MSM. Chemsex and use of two individual chemsex drugs
(mephedrone and GHB/BGL) significantly declined over time among
individuals in the study, as did most of the measures of sexual beha-
viour except for CLAI with one or more and two or more partners.
Whilst the majority of MSM in the study did not report chemsex, there is
a clear need for integrated drug and sexual health services, with a focus
on health promotion and HIV prevention, such as PEP and PrEP access,
aimed at MSM who report chemsex, and in particular problematic
chemsex. Such targeted interventions would be highly beneficial, po-
tentially only necessary for relatively short periods of time for in-
dividuals, and could have long term benefits as well as wider HIV and
STI prevention.
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